Fuente: Prohibición Partners Lugar: Uncategorized The cannabis industry generates more market research than almost any sector of its size. A search for cannabis market data will return dozens of reports, forecasts, and dashboards — many priced at thousands of dollars, most making bold claims about market size and growth trajectories. 



But the quality gap between the best and worst cannabis market research is enormous, and the cost of making decisions based on poor data is real. This guide is designed to help investors, operators, and analysts evaluate what they’re buying before they buy it.



Why Cannabis Market Research Is Uniquely Difficult



Most industries have established, standardised data infrastructure. Pharmaceutical markets have IMS Health. Consumer goods have Nielsen. Equities have Bloomberg. Cannabis has none of these — and the reasons matter for anyone consuming cannabis market data.



The sector operates across a patchwork of national and subnational regulatory frameworks, each with different reporting requirements, different definitions of what counts as “medical” vs “recreational,” and wildly different levels of transparency. In the United States, federal illegality means there is no single national dataset. In Europe, each country’s health authority collects and publishes data differently — some monthly, some annually, some not at all.



This fragmentation creates two problems for buyers of cannabis market research. First, the barriers to producing genuinely rigorous data are high, which means fewer providers do it well. Second, the barriers to producing plausible-looking but poorly sourced data are low, which means the market is flooded with reports that look authoritative but aren’t.



Understanding the difference between these two categories is worth the time for anyone making commercial decisions in cannabis.



The Cannabis Market Research Landscape



The providers of cannabis market intelligence broadly fall into four categories, each with different strengths, limitations, and use cases.



Generic market research firms — publish cannabis reports as part of their coverage of hundreds of industries. These reports typically offer broad global or regional market sizing, segmentation by product type and geography, and high-level CAGR forecasts. They are useful for initial orientation and for procurement teams who need an independent market size number for a business case. Their limitation is depth: the analysts writing these reports are typically generalists covering many sectors, the methodology sections are often vague, and the underlying data sources are rarely specified in granular detail. Prices range from around $3,000 to $5,000 or more for a single report.



Cannabis-specialist data platforms — focus exclusively on the cannabis sector and offer subscription-based access to ongoing data feeds. Headset, for example, tracks point-of-sale data from over 3,500 retail partners in the US and Canada, giving real-time visibility into consumer purchasing patterns, brand performance, and pricing trends. These platforms are strong on operational and retail-level intelligence, particularly in North American markets. Their limitation is geographic: coverage outside North America is limited, and the European medical cannabis market — where most of the regulatory and commercial action is happening in 2026 — is largely outside their scope.



Industry news and intelligence providers — such as Business of Cannabis and Cannabis Health News — publish ongoing market coverage, data snapshots, and periodic deep-dive analyses. These are valuable for staying current and for the contextual understanding that pure data alone cannot provide. The trade-off is that their coverage is typically broader than deep — a quarterly market update will give you the headline numbers, but not necessarily the granular monthly dataset you need for financial modelling.



Specialist research & analysis publishers — including Prohibition Partners — produce focused, single-market or single-topic reports designed for professional decision-making. These vary enormously in quality, but the best examples are distinguished by primary-source data access, transparent methodology, and analytical depth that goes beyond size-and-forecast summaries. These reports typically cost less than the generic firm offerings (£300–£1,000 vs $3,000–$5,000) and deliver more actionable intelligence for the specific markets they cover.



How to Evaluate a Cannabis Market Research Report



Not all reports are created equal, and the differences that matter are not always visible from a table of contents or executive summary. Here is what to look for — and what to question — when evaluating cannabis market intelligence.



Where does the data actually come from? This is the single most important question and the one most often left unanswered. A report that cites “proprietary models” or “industry estimates” without specifying primary data sources should be treated with caution. The gold standard is government-source or regulator-source data: pharmacy dispensing records, import/export statistics from health authorities, licensing data from regulatory bodies. These are verifiable, auditable, and not subject to the sampling biases that affect survey-based or POS-based approaches.



For example, Prohibition Partners’ Poland Medical Cannabis Market Review is built on dispensing records obtained directly from Centrum e-Zdrowia, Poland’s national health data authority. Every data point is traceable to a government source. That level of provenance is rare in cannabis market research, and it matters — especially when the numbers are being used to inform investment decisions or board-level strategy.



Is the data primary or derived? Many cannabis market reports present data that has been modelled or estimated from secondary sources rather than obtained from primary reporting systems. There is nothing inherently wrong with modelling — all forecasts involve it — but buyers should understand the distinction. A report that presents modelled estimates as if they were observed data is misleading. Look for reports that clearly separate observed historical data from projected or estimated figures, and that explain the assumptions behind any modelling.



How granular is the data? Annual market size figures are useful for orientation but limited for decision-making. Monthly or quarterly data reveals patterns that annual aggregates obscure: seasonality, the impact of regulatory changes, price trends, and demand trajectories. If you are evaluating a market entry, pricing strategy, or investment thesis, you need time-series data at sub-annual resolution. Ask whether the report provides this, and if so, how many periods it covers.



Can you work with the data, or just read it? This is an underappreciated distinction. Many reports deliver data as static figures embedded in a PDF — useful for reading, but not for analysis. If you need to build your own scenarios, adjust assumptions, or integrate cannabis market data into a broader financial model, you need the data in a workable format. Some providers deliver Excel workbooks alongside their reports, but the quality varies. The critical test is whether the workbook contains live formulas that you can trace and modify, or whether it is simply a formatted table of static numbers exported from a PDF.



The Poland Medical Cannabis Market Review, for instance, ships with a 10-tab Excel workbook containing hundreds of live formulas across 84 months of data. Every calculated value — growth rates, FX-adjusted figures, price per gram — is a formula you can trace back to the source data and modify for your own analysis. That is a fundamentally different product from a PDF with charts.



Does the analysis explain why, not just what? The most valuable market research does not simply report numbers. It contextualises them. A report that tells you Poland’s cannabis market dispensed 5,450 kg in 2025 is useful. A report that explains how a telemedicine ban halved prescription volumes in late 2024, how the market restructured around physical clinics through 2025, and how prices compressed 28% as competitive dynamics shifted — that is the difference between data and intelligence.



How are forecasts constructed? Be sceptical of single-point forecasts that project a smooth growth curve years into the future. Cannabis markets are subject to regulatory shocks, policy reversals, and competitive disruptions that make point estimates unreliable. Look for scenario-based forecasting that presents multiple outcomes under different assumptions (base, bull, bear). This is more honest about uncertainty and more useful for planning purposes.



What Cannabis Market Research Costs — and What You Should Expect



Pricing in cannabis market research spans a wide range, and higher prices do not reliably indicate higher quality. As a general framework:



Generic global or regional reports from the large market research firms typically cost $3,000–$5,000 or more. These provide broad market sizing and segmentation but limited depth on any single market. They are most useful for teams that need a credible third-party number for a business case or investor presentation and are less useful for operational decision-making.



Specialist single-market reports from cannabis-focused publishers range from roughly £300 to £1,000. The best of these deliver deeper analysis, primary-source data, and working datasets for a fraction of the cost of the generic alternatives. They are most useful for teams making specific market entry, investment, or strategy decisions in the markets they cover.



Subscription data platforms typically charge $10,000–$50,000+ annually for ongoing access. These are best suited to large operators, multi-state operators, or investors who need continuous real-time data across multiple markets. For smaller teams or single-market questions, a focused report is usually more cost-effective.



The key question is not “what is the cheapest option?” but “what format and depth of data do I actually need to make the decision I’m facing?” A $4,000 generic report and a £399 specialist report may both contain useful information, but for a specific question — like “what is the realistic revenue trajectory for a cannabis import business targeting Poland?” — the specialist report will almost always deliver more actionable intelligence.



Key Markets to Watch in 2026



For anyone building or updating their cannabis market research library in 2026, the markets generating the most analytical demand are:



Germany — Europe’s largest medical cannabis market, estimated at around €670 million, is navigating proposed restrictions on telemedicine prescribing and mail-order dispensing that could significantly reshape the sector. Understanding the likely impact of these restrictions is a top priority for investors and operators in the European market.



Poland — The third-largest European medical cannabis market and the only one with granular enough data to model the full impact of telemedicine restrictions. Poland’s 84-month dataset, covering the complete cycle from telemedicine-driven growth through regulatory shock and market recovery, is increasingly referenced as a leading indicator for other European markets.



Australia — A rapidly growing medical cannabis market facing its own mounting scrutiny of telemedicine-driven prescribing models, with regulatory tightening expected through 2026.



United States — The rescheduling of cannabis from Schedule I to Schedule III, initiated by executive order in late 2025, has significant implications for taxation (removing the burden of Section 280E), banking access, and market structure. The US remains the world’s largest legal cannabis market.



United Kingdom — A small but growing medical cannabis market where private telemedicine clinics drive the majority of prescriptions. Regulatory and access developments continue to attract investor attention.







Prohibition Partners Reports



Prohibition Partners publishes focused market intelligence reports designed for professional decision-makers in the cannabis industry. Our reports are built on primary-source data, transparent methodology, and analytical depth — not generic templates.



Poland Medical Cannabis Market Review 2026 — The most comprehensive analysis of Poland’s medical cannabis market available. 84 months of government-source data, the complete telemedicine ban shock-and-recovery story, pricing dynamics, and three-scenario 2026–2027 forecasts. Includes an interactive Excel workbook with hundreds of live formulas. From £399.



Browse all Prohibition Partners reports →
The post Cannabis Market Research: A Buyer’s Guide to Reports, Data, and Market Intelligence appeared first on Prohibition Partners.